ArticleFunctional & integrative genomics2026
Transcriptional landscape of coding-noncoding RNA interactions in gallstone-associated and de-novo gallbladder carcinoma.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Gallbladder carcinoma (GBC) is an aggressive malignancy characterized by late-stage presentation, poor prognosis, and limited therapeutic options. Gallstones (GS) represent a major risk factor and are implicated in the majority of GBC cases; however, the molecular distinctions between GS-associated GBC (GBCGS) and GS-independent/de novo GBC (dnGBC) remain poorly defined. To date, no GBC subtype-specific molecular biomarkers have been established. In this study, we employed an integrative transcriptomic and systems biology framework to delineate coding and non-coding RNA signatures underlying GBC pathogenesis. Transcriptomic profiling was performed on tumor tissues representing dnGBC and GBCGS subtypes, followed by comprehensive computational analyses including differential expression analysis, protein-protein interaction (PPI) networks construction, lncRNA-mRNA correlation networks, and competing endogenous RNA (ceRNA) network integration to identify key regulatory nodes. Systems-level analysis revealed distinct pathway enrichments between the two subtypes, indicating molecular heterogeneity in their pathobiology. In dnGBC, lncRNA DIO3OS and a novel transcript MSTRG.16633.1 were identified as highly connected candidate regulatory lncRNAs associated with genes involved in cell adhesion molecule (CAM) pathways. In contrast, GBCGS was characterized by lncRNA LINC00852 and novel transcript MSTRG.53675.1, which were associated with hub mRNAs enriched in the oncogenic signaling pathway. Expression of candidate mRNAs and lncRNAs identified from network analyses were validated by quantitative RT-PCR. This pilot study highlights the complex molecular heterogeneity within the two GBC subtypes and identifies potential RNA signatures involved in dnGBC and GBCGS pathogenesis that may contribute to improved understanding of molecular stratification and targeted therapeutic development.
Indexed as
Identifiers
42474553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.